Objective. Mice of the MRL-lpr strain develop a severe autoimmune arthritic condition when primed with complete Freund's adjuvant. The pathology is similar to that seen in human rheumatoid arthritis. We investigated whether PK 11195, a powerful ligand for peripheral benzodiazepine receptors, would have preventative or therapeutic effects in this model.
Benzodiazepines were introduced into clinical medicine are known as PBR ligands. They have no well-defined pharmacological properties. in 1961. Their success as anxiolytic, sedative, hypnotic, PK 11195, the name commonly given to 1-(2-chloroanticonvulsant and muscle-relaxant drugs spurred an phenyl )-N-methyl-N-(1-methylpropyl )-1-isoquinoline immense amount of research into the structural requirecarboxamide, is one of the most powerful PBR ligands ments for efficacy and the precise mechanism of action.
known [2] . It binds to receptors on monocytes [4] and, It was found that agents possessing these neuropharmafollowing lesioning, the binding is upregulated in brain cological properties bound with high affinity to receptors macrophages [5] and reactive microglia [6 ] . PK 11195 which were concentrated in the brain. These became binding is sharply upregulated in multiple sclerosis [7] , known as central benzodiazepine receptors. It was later experimental autoimmune encephalitis ( EAE ) [7] , learned that they were subsets of GABA A receptors, and malignant gliosis [8-10] and Alzheimer's disease [11] . that benzodiazepine binding enhanced the inhibitory These conditions are all characterized by neuroinflamactivity of the neurotransmitter GABA (reviewed in [1]). matory changes. A by-product of this research was the discovery of a PK 11195 has been used as an imaging agent in separate class of benzodiazepines and related compositron emission tomography (PET ) studies, where it pounds which bound with high affinity to completely identifies multiple sclerotic plaques, malignant gliomas different receptors, which have been termed peripheral [12] [13] [14] and areas surrounding infarcted zones in stroke benzodiazepine receptors (PBRs) [2] . These receptors, [7, 12, 15] . Its apparent association with activated which have since been identified and cloned, are found microglia led us to hypothesize that PBRs might be in many tissues of the body, including brain. Their associated with inflammatory processes. To test whether precise functions are unknown (reviewed in [3] ).
PBRs might be associated with inflammation, and Compounds which bind to them with high affinity whether the powerful PBR ligand, PK 11195, might have anti-inflammatory properties, we investigated whether it would affect disease in the MRL-lpr mouse initially found to develop a severe and spontaneous autoimmune disorder sharing similarities with human To test the therapeutic effects of PK 11195, the same protocol was followed, except that administration of the rheumatoid arthritis (RA), Sjö gren's syndrome and systemic lupus erythematosus [16] [17] [18] [19] [20] [21] [22] . Continuous drug or DMSO vehicle was not commenced until day 10 after CFA administration. By day 10, most animals breeding in some colonies has resulted, for unknown reasons, in a reduction in the severity and frequency of display significant joint swelling (average increase of 0.185 mm). The final concentrations of PK 11195 in this the spontaneous rheumatic disease. As a consequence, arthritis in these mice must be induced for them to have series of experiments were equivalent to 0.03, 0.3 and 3 mg/kg/day. usefulness in assessing the efficacy of various experimental treatments.
Clinical and histological examination of joints We have utilized the injection of complete Freund's adjuvant (CFA) as a method of enhancing arthritis in
The presence of clinical disease (visual appearance of arthritis) was evaluated in all groups of mice every these MRL-lpr mice. Seventy-four per cent of mice injected with CFA at 13-14 weeks of age were found to 5 days and scored as positive if erythema and swelling of a fore or hind paw was observed. Bimaleolar ankle develop clinical signs of arthritis in the subsequent 2-4 weeks. Histopathological analysis demonstrated that the width measurements were also taken in all animals every 5 days (always prior to PK 11195 injection in the large and small joints of the hind limbs displayed a significant and reproducible articular pathology. The treatment group) using a micrometer. Thirty days after injection of adjuvant, all animals were killed using CO 2 changes included synovial cell proliferation, pannus formation and articular cartilage erosion adjacent to the asphyxiation, and the hind paws removed and placed in buffered formalin. Following removal of skin from the proliferating synovial cells. These arthritic changes are more severe than those observed in untreated animals joints, they were next placed for 48 h in 10% formic acid for decalcification, and processed for paraffin at a later age [23] . This model offers advantages over other arthritic models since the disease more closely embedding. Serial sections were cut to a thickness of 5 mm, and stained with haematoxylin and eosin. Sections resembles the pathology seen in human RA, and the early onset gives an opportunity to assess the effects of were examined and scored by a blinded observer. The following parameters were graded 0-2 as previously therapeutic interventions. It is considered to be a particularly demanding one for screening anti-inflammatory reported in detail [23] : (a) subsynovial inflammation (0, normal; 1, focal inflammatory infiltrates; 2, inflamagents because of the severity and comprehensiveness of the disease pathology.
matory infiltrate dominates the cellular histology); (b) synovial hyperplasia (0, normal; 1, a continuous minimum three-layer-thick synovial lining of one joint; 2, minimum three-layer-thick synovial lining detected in Materials and methods several joints); (c) cartilage erosion and pannus formaAnimals and treatment tion (0, normal; 1, pannus partially covers cartilage surfaces without evident cartilage loss; 2, pannus con-MRL-lpr mice were obtained from a breeding colony located in the animal facilities in the Department of nected to evident cartilage loss); (d ) bone destruction (0, normal; 1, detectable destruction of bone by pannus Oral Biology, University of British Columbia. This colony was established from stocks originally purchased or osteoclast activity; 2, pannus or osteoclast activity destroyed a significant part of the bone). from the Jackson Laboratories (Bar Harbor, ME, USA). Thirteen-to 14-week-old male and female mice Statistical analyses were injected intradermally at two thoracic sites with a priming dose of 0.05 ml CFA supplemented to 10 mg/ml Statistical comparison of paired sets of ankle width measurements and histopathological indices between with heat-inactivated Mycobacterium tuberculosis H37 RA (Difco, Detroit, MI, USA). The adjuvant was groups was determined using ANOVA followed by Student's t-tests with Holm's correction [24] for multiple prepared as a water in oil emulsion and administered with a 27 G needle. Control animals of the same strain comparisons. and age were injected with phosphate-buffered saline. The mice were subsequently maintained on a standard Results diet with water ad libitum.
To test the preventative effects of PK 11195, one Examples of the articular pathology developing in mice at day 30 following CFA injection are shown in Fig. 1 . experimental group was treated with daily injections of 0.1 ml of PK 11195 ( Tocris, Baldwin, MO, USA) disThickening of synovial tissue in a mouse injected only with CFA is illustrated in Fig. 1A and B. Similar solved in 25% ethanol in distilled water and another with daily injections of 0.1 ml of PK 11195 dissolved in synovial thickening with leucocyte infiltration is shown in a mouse receiving CFA plus DMSO vehicle in dimethylsulphoxide (DMSO), starting on the day of CFA induction (day 0). Final concentrations of Fig. 1C and D. Pannus formation in mice receiving CFA plus DMSO vehicle is shown in Fig. 1E and PK 11195 were equivalent to 1 or 3 mg/kg/day. Controls for these groups were injected with either 0.1 ml of 25% osteoclastic activity in Fig. 1F . By contrast, a normal appearing joint of an animal receiving 3 mg/kg of ethanol in distilled water or 0.1 ml of DMSO. Injections were given i.p. on a daily basis until killing on day 30.
PK 11195 starting at day 10 after CFA administration Significant differences between DMSO and PK 11195 groups are indicated by *P < 0.05; **P < 0.01; ***P < 0.001. aThe histopathological score is given as the mean ± ... for each index. See [23] for rating method.
is shown in Fig. 1G . Figure 1H is from an untreated arthritic scores with increasing doses, with the 3 mg/kg dose reaching statistical significance at the P < 0.001 mouse. Animals of this strain spontaneously develop joint disease starting at 4-5 months, and mild synovial level for the total score ( Table 2) . The therapeutic effect of 3 mg/kg of PK 11195 was thickening of the joint was observed in this 28-week-old animal. In each case, only one area of the joint is also evident through measurements of ankle width taken at 5 day intervals between initiation of treatment illustrated. Evaluation was based on an assessment of the whole joint.
at day 10 and killing at day 30. This is illustrated in Fig. 2 . The figure shows that ankle swelling had disapThe preventative effects of PK 11195 are shown in Table 1 , which compares inflammatory scores of drugpeared by day 30 in the mice treated with 3 mg/kg/day of PK 11195, while ankle swelling continued to increase treated vs vehicle-treated animals. Data for animals treated only with CFA are also given. The table indicates in the DMSO-vehicle-treated animals. that PK 11195 significantly reduced the severity of arthritis whether in ethanol or DMSO vehicle. The Discussion arthritic indices of vehicle-treated animals were highly comparable to each other and to CFA-only-treated
The data presented here show that PK 11195 at a dose of 1 mg/kg/day significantly inhibits the development of animals.
The therapeutic effects of PK 11195 were tested by arthritic joint disease in the MRL-lpr mouse model when administered from the time of CFA induction administering the agent in DMSO starting 10 days after CFA treatment. Three doses were tested: 0.03, 0.3 and ( Table 1) . More importantly, PK 11195 significantly inhibits established disease progression when adminis-3 mg/kg. There was a trend towards reduced total pany the lesions. It is also consistent with in vitro results, which we will report separately, showing that PK 11195 inhibits the respiratory burst of activated macrophages and inhibits their ability to secrete neurotoxic substances.
MRL-lpr mice are known to develop lesions that, in addition to RA, are analogous to systemic lupus erythematosus and Sjö gren's syndrome. The CFA induction method employed in this study selectively enhances the rheumatoid arthritic component. Further research should be directed towards defining whether PK 11195 might similarly combat the other components of the spontaneous MRL-lpr disease with a view to the possible Acknowledgements tered at day 10 after CFA induction ( Table 2 and Fig. 2) [11] , where inflammation is known to accom-
